Antisense Inhibitors, Ribozymes, and siRNAs

作者：Thompson Alexander J V; Patel Keyur^*

来源：Clinics in Liver Disease, 2009, 13(3): 375-+.

DOI：10.1016/j.cld.2009.05.003

• Chronic hepatitis C
• Antisense
• Oligonucleotide
• Ribozyme
• siRNA
• shRNA
• RNA interference

The current standard of care for the treatment of hepatitis C virus infection, pegylated interferon-a and ribavirin, is costly, associated with significant side effects, and effective in only 50% of patients. There is therefore a need for the development of novel antiviral therapies. One such approach involves the application of gene silencing technologies, including antisense oligonucleotides, ribozymes, RNA interference, and aptamers. However, despite great scientific advances over the past decade, and promising in vitro data, several significant challenges continue to limit the translation of this technology to the clinical setting. This review provides a concise update of the current literature.

• 出版日期2009-8